Page last updated: 2024-12-05

2,5-dichlorobenzoquinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,5-dichlorobenzoquinone: an intermediate in gamma-hexachlorocyclohexane degradation by Xanthomonas [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID12011
CHEMBL ID3311439
SCHEMBL ID57290
MeSH IDM0516373

Synonyms (39)

Synonym
AC-4635
AKOS015849004
615-93-0
nsc-6251
p-benzoquinone,5-dichloro-
nsc6251
2,4-dione, 2,5-dichloro-
2,5-dichloro-p-benzoquinone
p-benzoquinone, 2,5-dichloro-
2,5-dichloro-1,4-benzoquinone
einecs 210-453-8
nsc 6251
2,5-dichlorobenzo-1,4-quinone
inchi=1/c6h2cl2o2/c7-3-1-5(9)4(8)2-6(3)10/h1-2
2,5-cyclohexadiene-1,4-dione, 2,5-dichloro-
2,5-dichloro-1,4-benzoquinone, 98%
SR-01000641767-1
D0343
2,5-dichloro-p-quinone
2,5-dichlorocyclohexa-2,5-diene-1,4-dione
A21114
2,5-dicb
CCG-52536
FT-0610320
SCHEMBL57290
CHEMBL3311439
DTXSID9060657
2,5-dichloro-2,5-cyclohexa-diene-1,4-dione
2,5-dichoro-p-benzoquinone
2,5-dichlorobenzo-1,4-quinone #
2,5-dichlorobenzoquinone
mfcd00041736
C21104
AS-64949
2.5-dichloro-p-benzoquinone
D83014
SY051216
CS-0157774
PD138965
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (1)

PathwayProteinsCompounds
2,4,5-trichlorophenoxyacetate degradation622

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1676053Irreversible inhibition of recombinant Clostridium botulinum N-terminal 6His-tagged BoNT/A (1 to 425 residues) light chain expressed in Escherichia coli BL21 (DE3) assessed as ratio of Kinact/Ki2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Catch and Anchor Approach To Combat Both Toxicity and Longevity of Botulinum Toxin A.
AID1181943Glutathione reactivity at 1 mM in presence of 1 mM glutathione containing PBS and 1 mM EDTA buffer at pH 7.4 assessed as remaining GSH level after 10 seconds by spectrophotometry by Ellman's method2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Benzoquinones as inhibitors of botulinum neurotoxin serotype A.
AID1181939Inhibition of recombinant Clostridium botulinum neurotoxin serotype A light chain assessed as Kinact to KI ratio at 50 uM after 1.5 hrs by SNAPtide FRET based assay2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Benzoquinones as inhibitors of botulinum neurotoxin serotype A.
AID1181944Glutathione reactivity at 1 mM in presence of 1 mM glutathione containing PBS and 1 mM EDTA buffer at pH 7.4 assessed as remaining GSH level after 30 mins by spectrophotometry by Ellman's method2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Benzoquinones as inhibitors of botulinum neurotoxin serotype A.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's5 (55.56)24.3611
2020's3 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.05 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index5.35 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]